Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ADA | P00813 | 1/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.34 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6425210 | 0.81 | ADORA2A (0.51) | ADORA3ADORA2AADASLC29A1ADORA2B | |
| SCHEMBL6838033 | 0.81 | ADORA2A (0.44) | ADORA3ADORA2AADASLC29A1ADORA2B | |
| SCHEMBL6838307 | 0.81 | ADORA2A (0.47) | ADORA3ADORA2AADASLC29A1ADORA2B | |
| SCHEMBL2595018 | 0.78 | SLC29A1 (0.48) | ADORA3SLC29A1 | |
| SCHEMBL1375866 | 0.78 | SLC29A1 (0.48) | ADORA3SLC29A1 | |
| SCHEMBL18025737 | 0.76 | SLC29A1 (0.43) | SLC29A1 | |
| SCHEMBL12464370 | 0.76 | SLC29A1 (0.43) | SLC29A1 | |
| SCHEMBL12464623 | 0.76 | SLC29A1 (0.43) | SLC29A1 | |
| SCHEMBL9127598 | 0.76 | SLC29A1 (0.43) | SLC29A1 | |
| SCHEMBL9127601 | 0.76 | SLC29A1 (0.43) | SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | claimed |
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | HAVCR2, PNP, NTPCR | ADORA3 170/4885ADORA2A 174/4885GAA 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.